K. Patrick Seastedt, MD, FACS

Curious about AI/Machine Learning as a Thoracic Surgeon? Check out our review on artificial intelligence applications in thoracic surgery and what the future may hold, out now in @EACTS_Journals. @ammara_a @Laparoscopes @BIDMCSurgery: academic.oup.com/ejcts/advance-…

@Laparoscopes @NIH Thanks, Dan! That means a lot coming from you. I’m really grateful for your mentorship and friendship over the past few years

@SeastedtMD @NIH Congrats!!! A great testament to the amazing work you do

Truly humbled and grateful to receive @NIH-supported K12 career development funding. Our project focuses on personalizing lung cancer survivorship using multimodal AI to predict recurrence and second primary cancers after surgery. Today most patients follow the same surveillance schedule despite very different risks. Our goal is to move toward risk-adapted follow-up based on clinicopathologic data and imaging. Thankful for incredible mentors, collaborators, and trainees who made this possible. Excited for the work ahead. @SidhuGang @ChiFuJeffYang @Jacobs_Med_UB @RoswellPark @Laparoscopes @FilicoriMD @UBuffalo @LindaMThoracic @BrendonStilesMD

Presented our work at the @wacv_official WACV 2026 Pixels-to-Patients Workshop. We developed MIRACLE — an LLM-augmented multimodal model for predicting postoperative complications after lung cancer surgery. The goal: AI that surgeons can understand, interrogate, and intervene on, not just accept as a black box. Great collaboration between UB Computer Science (@UBuffalo @Jacobs_Med_UB) and @RoswellPark. Paper: openaccess.thecvf.com/content/WACV20…

Appreciative of the opportunity to speak at @21Ccss and @SAGES_Updates Next Big Thing on AI in thoracic surgical oncology. Core thesis: In surgery, AI must function like an instrument, constrained, surgeon-directed, and anchored to outcome-based probability. Looking forward to how this conversation continues in upcoming thoracic meetings! @ElliotServaisMD @ShandaBlackmon @ChiFuJeffYang

@GenThorSurgClub Calling all 🫁 surgeons- Register now to avoid the inevitable #FOMO @STS_CTsurgery @lcsmchat @AATSHQ @ThoracicStudent @TSRA_official

Please take a few minutes to read this moving story by @SimarSBajaj in @nytimes about the soul-crushing weight of stigma that so many people with lung cancer carry every day. I was nearly in tears reading it. We must do a better job of destigmatizing lung cancer. No patient should ever be made to feel this alone. I also want to express my deepest gratitude to Ms. Cottrill, Ms. Padua-Reyes, and Mr. Pantelas for sharing your stories. I am profoundly grateful for your courage in opening up about such deeply personal experiences—your voices matter, and they are changing lives. Link: nytimes.com/2026/01/14/wel…

🎉 Oral @ WACV 2026 (P2P-CV Workshop) 🎉 Our paper introducing MIRACLE was accepted for oral presentation. We show an LLM-augmented, multimodal, human-in-the-loop model that predicts post-op complications after lung cancer surgery using clinical data + CT radiomics + editable explanations. Key idea: clinicians can intervene on explanations and change model outputs - bridging performance, interpretability, and real clinical use. Validated on 3,094 real-world patients. Preprint: lnkd.in/gq2dHsy4 Code: lnkd.in/gwEa4n7v #WACV2026 #P2PCV #MedicalAI #ExplainableAI #Multimodal #Surgery #LLMs @FilicoriMD @ChiFuJeffYang @Laparoscopes @RoswellPark @UBuffalo @wacv_official

💬Happy to share the Special Issue "Thoracic Cancer Surgery: From Classic to Robotic Approaches" edited by Prof. Dr. Sai Yendamuri and Dr. Kenneth Patrick Seastedt @SeastedtMD, @RoswellPark👏 📆Deadline is 15 June 2026 Find more details here👉mdpi.com/journal/cancer…

📢 Big win for lung cancer screening in NY!!! Governor Hochul just signed bill S2000A into law which will now require insurance plans to fully cover lung cancer screening & any follow up diagnostic testing without copay — removing a major financial barrier to lifesaving care!! Congratulations to the @RoswellPark team for your leadership on this landmark bill!!

A really important read by Dr. Douglas Wood (@DouglasEWood1 ) on why we should simplify lung cancer screening eligibility criteria, as NCCN recommends, to save more lives: seattletimes.com/opinion/early-… via @seattletimes #screeningsaveslives #lungcancerscreening #PotterCriteria

I feel compelled to circle back to this "bombshell" revelation posted on CTSNET. I don't intend to criticize my surgical colleagues, but I fail to understand the rationale for this webinar or how they reached the supposed "bombshell" conclusions... ctsnet.org/article/bombsh…

Must-read in @nytimes today on Women in Thoracic Surgery (@WomenInThoracic) led by the amazing Dr. Mara Antonoff (@maraantonoff)!! nytimes.com/2025/11/29/hea… This article features several renowned surgeons, who are pioneers, advancing the field of cardiothoracic surgery. One of them is my mentor, Dr. Leah Backhus (@leahbackhusmd), a phenomenal surgeon, researcher and educator whom I am so grateful to have had the opportunity to learn from ever since I was a fellow.

Today, the Washington Post covered the JAMA study by Bandi et al. about the untapped potential of lung cancer screening here & Dr. Narjust Florez's EQUAL study!!! wapo.st/48n94HE Here is the original JAMA study: ja.ma/3X6e5it We wrote an editorial about the study here: ja.ma/3K7qcsC

Just out from @myESMO After #FLOT became SOC for resectable gastric & GEJ adenocarcinoma, we wondered about adding #immunotherapy . Earlier this year, #MATTERHORN showed a big EFS win for #DFLOT, along w/ higher pCR & MPR rates, but the question was, what about OS? Answer: YES! 🧬 OS HR 0.78 (95% CI 0.63–0.96, p=0.021) 💪 Benefit seen across PD-L1 subgroups (TAP <1% HR 0.79; TAP ≥1% HR 0.79) 🫁 More nodal downstaging: ypN(-) 58% vs 45%, OR 1.72 (1.30–2.27) ⏱️ EFS improved in those w pCR (HR 0.29) & MPR (HR 0.32) Summary: Periop #chemoimmunotherapy is here for gastric & GEJ adenocarcinoma. MATTERHORN delivers the OS confirmation we needed & cements DFLOT as SOC @STS_CTsurgery @ASCO @AATSHQ @AstraZeneca #ESMO25 @OfficialSTSA

From a new @TheLancet article today entitled "Health care in the USA: money has become the mission" thelancet.com/journals/lance…

#ESMO25 Lung mini orals🔥 Ph III LungMATE-013 academic trial neoadj chemIO x 4 unresectable IIIB/C NSCLC ➡️surgery v chemo (randomized) - 100pts - 50 randomized sx v RT - pCR 47% - EFS HR favors surgery 0.38 Some disruptive science right here #ESMO25 #ESMOAmbassadors @myESMO

#ESMO25 | LungMate-013 Trial Induction serplulimab + chemotherapy followed by surgery vs radiotherapy in initially unresectable stage IIIB–IIIC NSCLC. 🔹 Patients converted to resectable disease and undergoing surgery achieved better EFS (HR 0.38; 95% CI 0.14–1.01). 🔹 Median EFS ≈ 17.7 months overall. 🔹 However, experts raised an important point — was radiotherapy alone the right comparator? Concurrent chemoradiation is the standard backbone, so results should be interpreted with caution. Still, the trial brings renewed attention to the potential role of conversion surgery after effective induction immunochemotherapy in locally advanced NSCLC @OncoAlert @OncoReporte @weoncologists @MedwatchKate @_SEOM @Lung_Cancers

Definitely wow!